Compound · clinical trials

RC148 clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 8 trials in our China register that name RC148 as an intervention. Synced 9 Nov 2026

8Current trials

4Recruiting now

1Lead sponsor

1Country register

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

RC148 is named as an intervention in 8 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is RemeGen Co., Ltd. The most-studied condition is Non-Small Cell Lung Cancer.

Patient leaflets for RC148

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting450%
Not yet open338%
Active, closed113%

Trials by phase

Phase 2338%
Phase 3225%
Phase 1113%
Phase 2/3113%
Phase 1/2113%

Clinical trials of RC148

8 trials

Study	Phase	Status	Lead sponsor	Registers
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) NCT07416474 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Recruiting	RemeGen Co., Ltd	China
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer NCT07462143 · ClinicalTrials.gov ↗ · Colorectal (Colon or Rectal) Cancer	Phase 2/3	Recruiting	RemeGen Co., Ltd	China
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer NCT06642545 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	RemeGen Co., Ltd	China
A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors NCT06016062 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	RemeGen Co., Ltd	China
Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations NCT07829549 · ClinicalTrials.gov ↗ · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations	Phase 3	Not yet open	RemeGen Co., Ltd	China
Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer NCT07874282 · ClinicalTrials.gov ↗ · Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology	Phase 2	Not yet open	RemeGen Co., Ltd	China
Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer NCT07895355 · ClinicalTrials.gov ↗ · Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy	Phase 2	Not yet open	RemeGen Co., Ltd	China
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC NCT06883630 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 1	Active, closed	RemeGen Co., Ltd	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with RC148

7 conditions

Non-Small Cell Lung Cancer2Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations1Colorectal (Colon or Rectal) Cancer1Breast Cancer1 Solid Tumor1Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology1Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy1

By country register

Register	Trials	Recruiting
Clinical trials in China	8	4

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about RC148 trials

How many clinical trials are testing RC148?

8 current trials in our China register name RC148 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are RC148 trials recruiting patients?

Yes. 4 of the 8 trials are recruiting: 4 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors RC148 clinical trials?

The lead sponsor is RemeGen Co., Ltd. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how RC148 works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RC148 works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RC148 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.